These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 19903902)

  • 21. Antibodies in the treatment of lymphoma.
    Leonard JP
    Clin Adv Hematol Oncol; 2004 Apr; 2(4):210-1. PubMed ID: 16163182
    [No Abstract]   [Full Text] [Related]  

  • 22. High CD206 levels in Hodgkin lymphoma-educated macrophages are linked to matrix-remodeling and lymphoma dissemination.
    Arlt A; von Bonin F; Rehberg T; Perez-Rubio P; Engelmann JC; Limm K; Reinke S; Dullin C; Sun X; Specht R; Maulhardt M; Linke F; Bunt G; Klapper W; Vockerodt M; Wilting J; Pukrop T; Dettmer K; Gronwald W; Oefner PJ; Spang R; Kube D
    Mol Oncol; 2020 Mar; 14(3):571-589. PubMed ID: 31825135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein.
    Hara I; Takechi Y; Houghton AN
    J Exp Med; 1995 Nov; 182(5):1609-14. PubMed ID: 7595233
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor dormancy and cell signaling. II. Antibody as an agonist in inducing dormancy of a B cell lymphoma in SCID mice.
    Racila E; Scheuermann RH; Picker LJ; Yefenof E; Tucker T; Chang W; Marches R; Street NE; Vitetta ES; Uhr JW
    J Exp Med; 1995 Apr; 181(4):1539-50. PubMed ID: 7535341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma.
    Palomba ML; Roberts WK; Dao T; Manukian G; Guevara-Patiño JA; Wolchok JD; Scheinberg DA; Houghton AN
    Clin Cancer Res; 2005 Jan; 11(1):370-9. PubMed ID: 15671568
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Therapeutic effect of agonistic CD40 monoclonal antibody combined with CTL on hu-SCID mouse B lymphoma model].
    Zhou H; Xi H; Ma QR; Chen C; Zhang F; Zhang XG; Gu ZJ
    Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):181-5. PubMed ID: 17649632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma.
    Rankin CT; Veri MC; Gorlatov S; Tuaillon N; Burke S; Huang L; Inzunza HD; Li H; Thomas S; Johnson S; Stavenhagen J; Koenig S; Bonvini E
    Blood; 2006 Oct; 108(7):2384-91. PubMed ID: 16757681
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts.
    Tuscano JM; O'Donnell RT; Miers LA; Kroger LA; Kukis DL; Lamborn KR; Tedder TF; DeNardo GL
    Blood; 2003 May; 101(9):3641-7. PubMed ID: 12511412
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD30-specific AB1-AB2-AB3 internal image antibody network: potential use as anti-idiotype vaccine against Hodgkin's lymphoma.
    Pohl C; Renner C; Schwonzen M; Schobert I; Liebenberg V; Jung W; Wolf J; Pfreundschuh M; Diehl V
    Int J Cancer; 1993 May; 54(3):418-25. PubMed ID: 8389737
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bone marrow stromal antigen 2 expressed in cancer cells promotes mammary tumor growth and metastasis.
    Mahauad-Fernandez WD; DeMali KA; Olivier AK; Okeoma CM
    Breast Cancer Res; 2014 Dec; 16(6):493. PubMed ID: 25499888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of CD40 stimulation in the prevention of human EBV-lymphomagenesis.
    Funakoshi S; Taub DD; Asai O; Hirano A; Ruscetti FW; Longo DL; Murphy WJ
    Leuk Lymphoma; 1997 Jan; 24(3-4):187-99. PubMed ID: 9156649
    [TBL] [Abstract][Full Text] [Related]  

  • 32. T-cell infiltrate after monoclonal anti-CD20 antibody therapy for B-cell lymphoma.
    Vincent-Salomon A; Mathiot C; Macintyre E; Girre V; Fourquet A; Mercier C; Fréneaux P; Dumont J; Decaudin D
    Leuk Lymphoma; 2000 Apr; 37(3-4):387-91. PubMed ID: 10752990
    [No Abstract]   [Full Text] [Related]  

  • 33. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.
    Schmidt-Wolf IG; Negrin RS; Kiem HP; Blume KG; Weissman IL
    J Exp Med; 1991 Jul; 174(1):139-49. PubMed ID: 1711560
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells.
    Rowan W; Tite J; Topley P; Brett SJ
    Immunology; 1998 Nov; 95(3):427-36. PubMed ID: 9824507
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer.
    Wente MN; Jain A; Kono E; Berberat PO; Giese T; Reber HA; Friess H; Büchler MW; Reiter RE; Hines OJ
    Pancreas; 2005 Aug; 31(2):119-25. PubMed ID: 16024997
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas.
    Funakoshi S; Longo DL; Murphy WJ
    J Immunother Emphasis Tumor Immunol; 1996 Mar; 19(2):93-101. PubMed ID: 8732692
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel non-lineage antigen on human leucocytes: characterization with two CD-48 monoclonal antibodies.
    Henniker AJ; Bradstock KF; Grimsley P; Atkinson MK
    Dis Markers; 1990; 8(4):179-90. PubMed ID: 2088634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulation of B-cell lymphoma growth in syngeneic SJL/J mice. establishment of tumor dormancy following administration of anti-CD4 monoclonal antibody into tumor-bearing mice.
    Ohnishi K; Bonavida B
    Leukemia; 1993 Nov; 7(11):1801-6. PubMed ID: 8231249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine.
    Guinn BA; DeBenedette MA; Watts TH; Berinstein NL
    J Immunol; 1999 Apr; 162(8):5003-10. PubMed ID: 10202049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
    Rodig SJ; Abramson JS; Pinkus GS; Treon SP; Dorfman DM; Dong HY; Shipp MA; Kutok JL
    Clin Cancer Res; 2006 Dec; 12(23):7174-9. PubMed ID: 17145843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.